Cargando…

Evaluating Ischemia-Modified Albumin as an Early Biomarker for Hypertensive Disorders During Pregnancy: A Case-Control Study

Background Ischemia-modified albumin (IMA) is looked upon as a newer marker of myocardial ischemia. There is a paucity of literature however with regard to studies correlating levels of IMA in patients with hypertensive disorders of pregnancy. The present study therefore aimed at estimating the leve...

Descripción completa

Detalles Bibliográficos
Autores principales: John, Jyoti E, Sakarde, Apurva, Misra, Swayam Swaroop, Mundle, Shuchita, Jose, Jancy, Tripathi, Satyendra Chandra, Amle, Dnyanesh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9706492/
https://www.ncbi.nlm.nih.gov/pubmed/36457615
http://dx.doi.org/10.7759/cureus.30867
_version_ 1784840516748181504
author John, Jyoti E
Sakarde, Apurva
Misra, Swayam Swaroop
Mundle, Shuchita
Jose, Jancy
Tripathi, Satyendra Chandra
Amle, Dnyanesh
author_facet John, Jyoti E
Sakarde, Apurva
Misra, Swayam Swaroop
Mundle, Shuchita
Jose, Jancy
Tripathi, Satyendra Chandra
Amle, Dnyanesh
author_sort John, Jyoti E
collection PubMed
description Background Ischemia-modified albumin (IMA) is looked upon as a newer marker of myocardial ischemia. There is a paucity of literature however with regard to studies correlating levels of IMA in patients with hypertensive disorders of pregnancy. The present study therefore aimed at estimating the levels of IMA in patients with gestational hypertension and assessing its utility in predicting hypertensive disorders of pregnancy. Methods The present study was a hospital-based case-control study conducted in the Department of Biochemistry, All India Institute of Medical Sciences (AIIMS), Nagpur. IMA was estimated in 30 controls (Group I) and 20 cases of gestational hypertension (Group II) using a spectrophotometric assay detecting free unbound Cobalt left behind. The clinical data and lab results were presented as mean ± SD. Student’s t-test was applied and Pearson’s correlation coefficient was calculated. A value of p < 0.05 was taken as statistically significant. The ROC (Receiver Operator Characteristic) curve was used to establish the cut-off of serum IMA levels in pregnancy-induced hypertension (PIH). Results There was no significant difference in age and period of gestation (POG) at the time of sample collection between the groups. There was a significant difference in the systolic and diastolic blood pressures (BPs) of both groups. The mean level of serum IMA was significantly higher in cases of gestational hypertension (0.88 ± 0.14 absorbance units {ABSU}) as compared to controls (0.69 ± 0.08 ABSU) (p<0.001). On correlation analysis, the systolic and diastolic BPs were found to be highly positively correlated with serum IMA levels (p<0.001). ROC curve analysis suggested that at a cut-off of 0.73 ABSU, IMA has 85% sensitivity and 80% specificity for predicting gestational hypertension. Conclusion Statistically significant results of serum IMA levels obtained in gestational hypertension which falls on the lesser severe spectrum of the disease imply that serum IMA can be used for early diagnosis of gestational hypertension and impending Pre-eclampsia (PE) and Eclampsia.
format Online
Article
Text
id pubmed-9706492
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-97064922022-11-30 Evaluating Ischemia-Modified Albumin as an Early Biomarker for Hypertensive Disorders During Pregnancy: A Case-Control Study John, Jyoti E Sakarde, Apurva Misra, Swayam Swaroop Mundle, Shuchita Jose, Jancy Tripathi, Satyendra Chandra Amle, Dnyanesh Cureus Endocrinology/Diabetes/Metabolism Background Ischemia-modified albumin (IMA) is looked upon as a newer marker of myocardial ischemia. There is a paucity of literature however with regard to studies correlating levels of IMA in patients with hypertensive disorders of pregnancy. The present study therefore aimed at estimating the levels of IMA in patients with gestational hypertension and assessing its utility in predicting hypertensive disorders of pregnancy. Methods The present study was a hospital-based case-control study conducted in the Department of Biochemistry, All India Institute of Medical Sciences (AIIMS), Nagpur. IMA was estimated in 30 controls (Group I) and 20 cases of gestational hypertension (Group II) using a spectrophotometric assay detecting free unbound Cobalt left behind. The clinical data and lab results were presented as mean ± SD. Student’s t-test was applied and Pearson’s correlation coefficient was calculated. A value of p < 0.05 was taken as statistically significant. The ROC (Receiver Operator Characteristic) curve was used to establish the cut-off of serum IMA levels in pregnancy-induced hypertension (PIH). Results There was no significant difference in age and period of gestation (POG) at the time of sample collection between the groups. There was a significant difference in the systolic and diastolic blood pressures (BPs) of both groups. The mean level of serum IMA was significantly higher in cases of gestational hypertension (0.88 ± 0.14 absorbance units {ABSU}) as compared to controls (0.69 ± 0.08 ABSU) (p<0.001). On correlation analysis, the systolic and diastolic BPs were found to be highly positively correlated with serum IMA levels (p<0.001). ROC curve analysis suggested that at a cut-off of 0.73 ABSU, IMA has 85% sensitivity and 80% specificity for predicting gestational hypertension. Conclusion Statistically significant results of serum IMA levels obtained in gestational hypertension which falls on the lesser severe spectrum of the disease imply that serum IMA can be used for early diagnosis of gestational hypertension and impending Pre-eclampsia (PE) and Eclampsia. Cureus 2022-10-30 /pmc/articles/PMC9706492/ /pubmed/36457615 http://dx.doi.org/10.7759/cureus.30867 Text en Copyright © 2022, John et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Endocrinology/Diabetes/Metabolism
John, Jyoti E
Sakarde, Apurva
Misra, Swayam Swaroop
Mundle, Shuchita
Jose, Jancy
Tripathi, Satyendra Chandra
Amle, Dnyanesh
Evaluating Ischemia-Modified Albumin as an Early Biomarker for Hypertensive Disorders During Pregnancy: A Case-Control Study
title Evaluating Ischemia-Modified Albumin as an Early Biomarker for Hypertensive Disorders During Pregnancy: A Case-Control Study
title_full Evaluating Ischemia-Modified Albumin as an Early Biomarker for Hypertensive Disorders During Pregnancy: A Case-Control Study
title_fullStr Evaluating Ischemia-Modified Albumin as an Early Biomarker for Hypertensive Disorders During Pregnancy: A Case-Control Study
title_full_unstemmed Evaluating Ischemia-Modified Albumin as an Early Biomarker for Hypertensive Disorders During Pregnancy: A Case-Control Study
title_short Evaluating Ischemia-Modified Albumin as an Early Biomarker for Hypertensive Disorders During Pregnancy: A Case-Control Study
title_sort evaluating ischemia-modified albumin as an early biomarker for hypertensive disorders during pregnancy: a case-control study
topic Endocrinology/Diabetes/Metabolism
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9706492/
https://www.ncbi.nlm.nih.gov/pubmed/36457615
http://dx.doi.org/10.7759/cureus.30867
work_keys_str_mv AT johnjyotie evaluatingischemiamodifiedalbuminasanearlybiomarkerforhypertensivedisordersduringpregnancyacasecontrolstudy
AT sakardeapurva evaluatingischemiamodifiedalbuminasanearlybiomarkerforhypertensivedisordersduringpregnancyacasecontrolstudy
AT misraswayamswaroop evaluatingischemiamodifiedalbuminasanearlybiomarkerforhypertensivedisordersduringpregnancyacasecontrolstudy
AT mundleshuchita evaluatingischemiamodifiedalbuminasanearlybiomarkerforhypertensivedisordersduringpregnancyacasecontrolstudy
AT josejancy evaluatingischemiamodifiedalbuminasanearlybiomarkerforhypertensivedisordersduringpregnancyacasecontrolstudy
AT tripathisatyendrachandra evaluatingischemiamodifiedalbuminasanearlybiomarkerforhypertensivedisordersduringpregnancyacasecontrolstudy
AT amlednyanesh evaluatingischemiamodifiedalbuminasanearlybiomarkerforhypertensivedisordersduringpregnancyacasecontrolstudy